Pulmonary Artery Sensor System Pressure Monitoring to Improve Heart Failure (HF) Outcomes

Inclusion Criteria

• •1. Written consent received from the patient or a legal representative after the in-formation has been provided.
• •2. ≥ 18 years of age.
• •3. Predominant symptoms in NYHA Stage III in the 30-day period prior to consent to the study.
• •4. Objectified HF diagnosis for more than three months.
• •5. Hospitalisation within 12 months prior to inclusion due to deterioration of HF symptoms.
• •6. Able to tolerate dual antiplatelet therapy or anticoagulation therapy for one month after sensor implantation
• •7. Patients with reduced left ventricular ejection fraction (LVEF) ≤40% (diagnosed within 6 months prior to inclusion) must be treated with guideline-compliant HF pharmacotherapy; if one class of guideline-compliant medication is not tolerated, appropriate documentation must be supplied; patients must receive and tolerate at least one class of guideline-compliant medication; if no guideline-compliant medication is tolerated at all, the patient may not participate in the study.
• •8. In patients with preserved LVEF (\>40%; diagnosed within 6 months prior to inclu-sion) comorbidities must be treated in accordance with guideline-compliant medi-cation.
• •9. Chest circumference (measured at axillary level) of less than 165 cm if BMI \>35 kg/m2.
• •10. Willing and mentally and physically able to meet the requirements for follow-up and long-term basic care (this includes the long-term willingness of the patient, and of their relatives where relevant, to participate in PA pressure-based monitor-ing).
• •11. Appropriate domestic situation, defined as being accessible by telephone (via fixed or mobile network) .